• CDMO provides Facilities Option for Integration Capability
    Rodolphe Clerval
  • Patrick Mahieux

News & Views

CDMO provides Facilities Option for Integration Capability

Clinical-stage biotech Coave Therapeutics focused on treatments for diseases of the eyes and central nervous system (CNS) is combining its expertise with that of contract development and manufacturing organisation ABL, a specialist in viruses for vaccine candidates, gene and cancer therapies, to co-develop manufacturing technologies for AAV-based gene therapy products.

Both companies will initially work together in ABL’s GMP facility in Lyon, France, with the second stage of the collaboration providing Coave with an option to secure its own process development capacity and laboratory space within ABL’s facility. This will enable the biotech to further develop and scale-up manufacturing technologies for AAV-based products, including its proprietary next-generation AAV-Ligand Conjugate vectors (ALIGATOR) platform.

“Our collaboration with ABL, a best-in-class and complementary partner for Coave, is a major step in our strategy towards the vertical integration of our R&D capacities, which will be crucial in enabling us to control the development and manufacture of our pipeline products in an end-to-end manner. The manufacturing processes developed through this partnership will be critical on the path to achieving our future clinical and commercial development milestones, in particular for our CNS programs addressing large patient populations,” said Rodolphe Clerval, CEO, Coave Therapeutics.

Patrick Mahieux, general manager, ABL Europe, said: “We are delighted to join forces with Coave, a fellow French company. This exclusive partnership aims to bring together our knowledge and expertise to co-develop a state-of-the-art manufacturing process for viral vectors used in cell and gene therapies. We are excited to welcome Coave’s team of expert scientists to our facilities in Lyon to jointly accelerate the development of an AAV manufacturing platform. We look forward to a long-term partnership enabling the development and manufacturing of innovative cell and gene therapy treatments in France.”

More information online


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

View all events